{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:47:22Z","timestamp":1767134842475,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd002007.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000}}],"reference-count":130,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002007.pub5","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T04:24:55Z","timestamp":1624422295000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis"],"prefix":"10.1002","volume":"2021","author":[{"given":"Poppy","family":"Holland","sequence":"additional","affiliation":[{"name":"West of Scotland Adult CF Unit; Queen Elizabeth University Hospital (The Southern General Hospital); Glasgow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Jahnke","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health; University of Liverpool; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"10.1002\/14651858.CD002007.pub5-BIB0001|cit1","unstructured":"Costantini D Padoan R Brienza A Lodi G Assael BM Giunta A Clinical evaluation of carbenicillin and sisomycin alone or in combination in CF patients with pulmonary exacerbations Proceedings of the 11th European Cystic Fibrosis Conference 1982 227"},{"issue":"3","key":"10.1002\/14651858.CD002007.pub5-BIB0002|cit2","first-page":"354","article-title":"Evaluation of antibiotic therapy in patients with cystic fibrosis","volume":"76","author":"Huang","year":"1979","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0003|cit3","unstructured":"Huang NN Palmer J Braverman S Keith HH Schidlow D Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study 23rd Cystic Fibrosis Club Abstracts; 1982 May 14; Washington DC 1982 124"},{"issue":"Suppl 25","key":"10.1002\/14651858.CD002007.pub5-BIB0004|cit4","first-page":"162s","article-title":"Once daily tobramycin monotherapy versus conventional antibiotic therapy for the treatment of pseudomonal pulmonary exacerbations in cystic fibrosis patients","volume":"10","author":"Master","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD002007.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ppul.1060","article-title":"Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study","volume":"31","author":"Master","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ppul.1950040403","article-title":"Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis","volume":"4","author":"McCarty","year":"1988","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD002007.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/infdis\/147.3.559","article-title":"Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin and azlocillin-placebo","volume":"147","author":"McLaughlin","year":"1983","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jac\/11.suppl_B.195","article-title":"Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis","volume":"11 Suppl B","author":"McLaughlin","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD002007.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3476(77)80790-7","article-title":"Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin","volume":"90","author":"Parry","year":"1977","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/00365548609032319","article-title":"Immediate and prolonged clinical efficacy of Ceftazidime versus Ceftazidime plus Tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"18","author":"Pedersen","year":"1986","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-3476(99)70197-6","article-title":"Comparison of a B-lactam alone versus B-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis","volume":"134","author":"Smith","year":"1999","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD002007.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcf.2010.09.003","article-title":"Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis","volume":"10","author":"Adeboyeku","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0013|cit13","first-page":"249","article-title":"A randomised cross over trial of TOBI\u00ab vs IV tobramycin in acute pulmonary exacerbations in CF","volume":"38 Suppl 27","author":"Al-Aloul","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002007.pub5-BIB0014|cit14","first-page":"ii79","article-title":"Tobramycin nebuliser solution (TOBI): a renal sparing alternative to intravenous (IV) tobramycin in acute pulmonary exacerbations in CF","volume":"59","author":"Al-Aloul","year":"2004","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002007.pub5-BIB0015|cit15","first-page":"ii92","article-title":"Tobramycin nebuliser solution in the treatment of cystic fibrosis pulmonary exacerbations: effect on sputum pseudomonas aeruginosa density","volume":"2","author":"Al-Aloul","year":"2005","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/jamp.2013.1055","article-title":"Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations","volume":"27","author":"Al-Aloul","year":"2014","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"issue":"5","key":"10.1002\/14651858.CD002007.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/ckj\/sfz005","article-title":"The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis","volume":"12","author":"Al-Aloul","year":"2019","journal-title":"Clinical Kidney Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002007.pub5-BIB0018|cit18","first-page":"iii85","article-title":"Efficacy of once daily tobramycin for acute pulmonary exacerbations of cystic fibrosis (CF) - a microbiological perspective [abstract]","volume":"56","author":"Al-Ansari","year":"2001","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD002007.pub5-BIB0019|cit19","first-page":"34","article-title":"Evaluation of once daily tobramycin versus the traditional three times daily for the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients [abstract]","volume":"15","author":"Al Ansari","year":"2006","journal-title":"Qatar Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jac\/dkf168","article-title":"Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis","volume":"50","author":"Aminimanizani","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Suppl 20","key":"10.1002\/14651858.CD002007.pub5-BIB0021|cit21","first-page":"284","article-title":"Pharmacokinetics of once-daily tobramycin in adult cystic fibrosis patients [abstract]","volume":"30","author":"Tsang","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0022|cit22","unstructured":"Balsamo V Bragion E Iapichino L Natozi D Pardo F Clinical efficacy and \"in vitro\" activity of some antibiotics, ceftazidime aztreonam or carbenicillin with aminoglycosides against Pseudomonas in Cystic fibrosis patients [abstract] 14th Annual Meeting of the European Working Group for Cystic Fibrosis 1986 63"},{"issue":"1","key":"10.1002\/14651858.CD002007.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3476(80)80155-7","article-title":"Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?","volume":"97","author":"Beaudry","year":"1980","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Beaudry PH Marks MI Rangel R McDougall D Desmond K Is anti-pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? [abstract] 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia 1979 1","DOI":"10.1016\/S0022-3476(80)80155-7"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0025|cit25","first-page":"370, Abstract n","article-title":"Safety, pharmacokinetics and preliminary evaluation of the antiinflammatory effect of doxycycline in CF [abstract]","volume":"45 Suppl 33","author":"Beringer","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD002007.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/AAC.05710-11","article-title":"Pharmacokinetics of doxycycline in adults with cystic fibrosis","volume":"56","author":"Beringer","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0027|cit27","first-page":"294","article-title":"Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of acute pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with Pseudomonas aeruginosa (PA) or Burkholderia cepacia (BC) [abstract]","volume":"Suppl 25","author":"Blumer","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1378\/chest.128.4.2336","article-title":"The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis","volume":"128","author":"Blumer","year":"2005","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0029|cit29","first-page":"R(c)17","article-title":"A comparative trial of aztreonam and tobramycin plus azlocillin [abstract]","volume":"74","author":"Bosso","year":"1988","journal-title":"Excerpta medica, Asia Pacific Congress Series"},{"issue":"3","key":"10.1002\/14651858.CD002007.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00006454-198803000-00008","article-title":"Controlled trial of aztreonam vs tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis","volume":"7","author":"Bosso","year":"1988","journal-title":"Pediatric Infectious Diseases Journal"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1569-1993(17)30168-6","article-title":"Longitudinal airway microbiota profiling in cystic fibrosis patients enrolled in the CFMATTERS clinical trial","volume":"16 (Supplement","author":"Einarsson","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0032|cit32","unstructured":"Cystic fibrosis microbiome-determined antibiotic therapy trial in exacerbations: results stratified (CFMATTERS) clinicaltrials.gov\/ct2\/show\/NCT02526004"},{"issue":"1","key":"10.1002\/14651858.CD002007.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199701000-00031","article-title":"Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime\/tobramycin in the treatment of acute pulmonary exacerbations","volume":"16","author":"Church","year":"1997","journal-title":"Pediatric Infectious Diseases Journal"},{"issue":"11","key":"10.1002\/14651858.CD002007.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/thx.52.11.987","article-title":"Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis","volume":"52","author":"Conway","year":"1997","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0035|cit35","unstructured":"Conway SP Pond M Watson A Robey H Goldman M A safety profile of intravenous colomycin in adult care [abstract] 20th European Cystic Fibrosis; 1995 June 18-21; Brussels, Belgium 1995 P3"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0036|cit36","first-page":"296","article-title":"Colistin alone or in combination with a second antibiotic is effective in the treatment of respiratory exacerbations in cystic fibrosis [abstract]","volume":"Suppl 13","author":"Conway","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD002007.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ppul.1950070310","article-title":"Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy","volume":"7","author":"Boeck","year":"1989","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0300-2977(99)90113-4","article-title":"Meropenem versus ceftazidime plus tobramycin for pulmonary disease in CF patients [abstract]","volume":"54","author":"Boeck","year":"1999","journal-title":"The Netherlands Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002007.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-3476(87)80337-2","article-title":"Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease","volume":"111","author":"Donati","year":"1987","journal-title":"Journal of Pediatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002007.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1569-1993(17)30537-4","article-title":"Impact of intravenous antibiotics on the gut microbiota in children with cystic fibrosis","volume":"16","author":"Enaud","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl A","key":"10.1002\/14651858.CD002007.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jac\/12.suppl_A.331","article-title":"Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia","volume":"12","author":"Gold","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00006454-198503000-00012","article-title":"Controlled trial of ceftazidime vs ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis","volume":"4","author":"Gold","year":"1985","journal-title":"Pediatric Infectious Disease"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S26, Abstract n","DOI":"10.1016\/S1569-1993(13)60079-X","article-title":"Lung clearance index: a tool to assess the response to intravenous treatment among children with cystic fibrosis [abstract]","volume":"12 Suppl 1","author":"Hatziagorou","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/12.2.175","article-title":"Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis","volume":"12","author":"Hoogkamp-Korstanje","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD002007.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1128\/AAC.00174-09","article-title":"Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis","volume":"53","author":"Hubert","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0046|cit46","first-page":"294","article-title":"Continuous infusion versus intermittent administration of ceftazidime in cystic fibrosis patients [abstract]","volume":"Suppl 25","author":"Hubert","year":"2003","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0047|cit47","unstructured":"Continuous versus short infusions of ceftazidime in cystic fibrosis clinicaltrials.gov\/show\/NCT00333385"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0022-3476(81)80486-6","article-title":"A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis","volume":"99","author":"Hyatt","year":"1981","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0022-3476(85)80100-1","article-title":"Comparison of cefoperazone sodium vs methicillin, ticarcillin and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis","volume":"106","author":"Jewett","year":"1985","journal-title":"Journal of Pediatrics"},{"issue":"7","key":"10.1002\/14651858.CD002007.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.01797-10","article-title":"Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002007.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S39, Abstract n","DOI":"10.1016\/S1569-1993(09)60158-2","article-title":"Eradication of Pseudomonas aeruginosa in adults with CF [abstract]","volume":"8","author":"Kenny","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0052|cit52","first-page":"609","article-title":"The treatment of exacerbations of pulmonary disease in cystic fibrosis: netilmicin compared with netilmicin and carbenicillin","volume":"25","author":"Krause","year":"1979","journal-title":"Current Therapeutic Research Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00003072-199202000-00002","article-title":"Aerosol scintigraphy in the assessment of therapy for cystic fibrosis","volume":"17","author":"Kuni","year":"1992","journal-title":"Clinical Nuclear Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002007.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/10.3.227","article-title":"Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis","volume":"10","author":"Levy","year":"1982","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S71, Abstract n","DOI":"10.1016\/S1569-1993(13)60231-3","article-title":"Evaluation of a twice daily tobramycin regimen in adult cystic fibrosis patients [abstract]","volume":"12 Suppl 1","author":"McCabe","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ppul.21350","article-title":"Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection","volume":"46","author":"Moskowitz","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0057|cit57","unstructured":"Standard vs. biofilm susceptibility testing in cystic fibrosis (CF) clinicaltrials.gov\/ct2\/show\/NCT00153634"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0058|cit58","unstructured":"What duration of intravenous antibiotic therapy should be used in the treatment of infective exacerbations of cystic fibrosis in patients chronically colonised with Pseudomonas aeruginosa? - Duration of antibiotics in infective exacerbations of cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-014042-28-GB"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0059|cit59","unstructured":"Duration of antibiotics in infective exacerbations of cystic fibrosis clinicaltrials.gov\/show\/NCT01044719"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0060|cit60","unstructured":"A study comparing continuous infusion antibiotics to standard treatment for lung infections in cystic fibrosis (CISTIC) clinicaltrials.gov\/ct2\/show\/NCT01667094"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0061|cit61","unstructured":"Continuous infusion piperacillin-tazobactam for the treatment of cystic fibrosis (PIPE-CF) clinicaltrials.gov\/ct2\/show\/NCT01694069"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0062|cit62","unstructured":"Population pharmacokinetics and safety of intravenous ceftolozane\/tazobactam in adult cystic fibrosis patients clinicaltrials.gov\/ct2\/show\/NCT02421120"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0063|cit63","unstructured":"IV colistin for pulmonary exacerbations: improving safety and efficacy clinicaltrials.gov\/ct2\/show\/NCT02918409"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0064|cit64","unstructured":"Evaluation of the efficacy of antibiotic treatments associated with the Nebcine\u00ae as intravenous injection only and \/ or monitoring of aerosols of Tobi\u00ae in order to optimize the therapeutic management of exacerbations in patients with cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-003882-10-FR"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0065|cit65","unstructured":"Evaluation of short antibiotic combination courses followed by aerosols in cystic fibrosis (TOBRAMUC) clinicaltrials.gov\/ct2\/show\/NCT03066453"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00006454-198607000-00014","article-title":"Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis","volume":"5","author":"Jackson","year":"1986","journal-title":"Pediatric Infectious Disease"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0022-3476(85)80264-X","article-title":"Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal","volume":"106","author":"Nelson","year":"1985","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0068|cit68","first-page":"332","article-title":"Comparison of antibiotics for early pseudomonas infection in CF: interim data analysis [abstract]","volume":"42 Suppl 30","author":"Noah","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD002007.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ppul.21176","article-title":"Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas","volume":"45","author":"Noah","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0070|cit70","unstructured":"Padoan R Cambisano W Constantini D Crossignani R Giunta A Pseudomonas pulmonary infections in cystic fibrosis: Ceftazidime vs ceftazidime plus sisomicin vs piperacillin plus sisomicin [abstract] 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England 1984 Poster 4.21"},{"issue":"7","key":"10.1002\/14651858.CD002007.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00006454-198707000-00006","article-title":"Ceftazidime monotherapy vs combined therapy in Pseudomonas pulmonary infections in cystic fibrosis","volume":"6","author":"Padoan","year":"1987","journal-title":"Pediatric Infectious Diseases Journal"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0072|cit72","unstructured":"Pharmacokinetics of tedizolid phosphate in cystic fibrosis clinicaltrials.gov\/show\/NCT02444234"},{"issue":"9","key":"10.1002\/14651858.CD002007.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"e00550","DOI":"10.1128\/AAC.00550-18","article-title":"Pharmacokinetics of tedizolid in plasma and sputum of adults with cystic fibrosis","volume":"62","author":"Park","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/ofid\/ofx163.670","article-title":"Pharmacokinetics of tedizolid in adults with cystic fibrosis","volume":"4","author":"Wang","year":"2017","journal-title":"Open Forum Infectious Diseases"},{"issue":"Suppl A","key":"10.1002\/14651858.CD002007.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/12.suppl_A.313","article-title":"Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis","volume":"12","author":"Permin","year":"1983","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0076|cit76","first-page":"299, Abstract n","article-title":"Are morning doses of intravenous tobramycin less nephrotoxic than evening? Evidence from urinary biomarkers in the critic study [abstract]","volume":"48 Suppl 36","author":"Prayle","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jcf.2015.07.012","article-title":"The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison","volume":"15","author":"Prayle","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD002007.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s15010-009-8117-4","article-title":"Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0079|cit79","unstructured":"Riethmueller J Busch A Franke P Ziebach R von Butler R Stern M Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF-patients is equally effective [abstract] 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden 2000 166"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0080|cit80","unstructured":"Riethmueller J Franke P Schroeter TW Claass A Busch A Ziebach R Optimised intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients [abstract] 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P192"},{"issue":"5","key":"10.1002\/14651858.CD002007.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s15010-009-8116-5","article-title":"Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0082|cit82","first-page":"289","article-title":"Acute-phase nephrotoxicity of tobramycin in CF patients: A prospective randomized trial of once-versus thrice-daily dosing [abstract]","volume":"Suppl 24","author":"Schroeter","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0083|cit83","unstructured":"Schroeter TW Eggert P Riethmueller J Stern M Claass A A prospective randomized trial on the nephrotoxicity of thrice-daily versus once-daily tobramycin in cystic fibrosis patients [abstract] 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P190"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2125.1993.tb00380.x","article-title":"An in vivo assessment of the tobramycin\/ticarcillin interaction in cystic fibrosis patients","volume":"36","author":"Roberts","year":"1993","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0085|cit85","first-page":"152","article-title":"Measurement of serum tobramycin in the presence of ticarcillin or piperacillin","volume":"22","author":"Roberts","year":"1992","journal-title":"Australian Journal of Hospital Pharmacy"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"S55, Abstract n","DOI":"10.1016\/S1569-1993(10)60215-9","article-title":"Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic pseudomonas aeruginosa infection [abstract]","volume":"9 Suppl 1","author":"Semykin","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD002007.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/thx.40.5.358","article-title":"Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms","volume":"40","author":"British Thoracic Society Research Committee","year":"1985","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0088|cit88","unstructured":"Stack BHR Geddes DM Williams KJ Dinwiddie R Selkon JB Godfrey RC Ceftazidime compared with a combination of gentamicin and carbenicillin in cystic fibrosis patients with persistent pulmonary pseudomonas infection and an acute exacerbation of respiratory symptoms [abstract] 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England 1984 4.16"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(18)30390-4","article-title":"Design, enrollment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations","volume":"17 Suppl 3","author":"Flume","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD002007.pub5-BIB0090|cit90","first-page":"388","article-title":"Design, enrolment, and feasibility of the STOP-2 randomised study of iv antibiotic duration in CF pulmonary exacerbations","volume":"52","author":"Heltshe","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cct.2017.11.012","article-title":"Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF","volume":"64","author":"Heltshe","year":"2018","journal-title":"Contemporary Clinical Trials"},{"issue":"S2","key":"10.1002\/14651858.CD002007.pub5-BIB0092|cit92","first-page":"324","article-title":"Update on the STOP-2 randomized study of IV antibiotic duration in CF pulmonary exacerbations","volume":"53","author":"Sanders","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD002007.pub5-BIB0093|cit93","first-page":"124","article-title":"Treatment of pulmonary exacerbations","volume":"52","author":"West","year":"2017","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002007.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(19)30118-3","article-title":"Comparative genomics study of a set of Pseudomonas aeruginosa isolates from the TORPEDO-CF trial","volume":"18","author":"Cazares","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0095|cit95","unstructured":"Trial of optimal therapy for pseudomonas eradication in cystic fibrosis - TORPEDO-CF www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-012575-10-SE"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0096|cit96","unstructured":"Trial of optimal therapy for pseudomonas eradication in cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN02734162"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002007.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1569-1993(17)30428-9","article-title":"TORPEDO-CF-completion of recruitment to trial of optimal regimen for eradication of new infection with Pseudomonas aeruginosa","volume":"16","author":"Langton Hewer","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD002007.pub5-BIB0098|cit98","first-page":"294","article-title":"Torpedo-CF - trial of optimal therapy for pseudomonas eradication in cystic fibrosis","volume":"53","author":"Langton Hewer","year":"2018","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(19)30117-1","article-title":"Effectiveness of IV compared to oral eradication therapy of Pseudomonas aeruginosa in cystic fibrosis: multicentre randomised controlled trial (TORPEDO-CF)","volume":"18 Suppl 1","author":"Langton Hewer","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD002007.pub5-BIB0100|cit100","first-page":"302","article-title":"Intravenous vs oral antibiotics for eradication of pseudomonas aeruginosa in cystic fibrosis (Torpedo-CF): a randomised controlled trial","volume":"54","author":"Smyth","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0101|cit101","unstructured":"TORPEDO-CF www.controlled-trials.com\/ISRCTN02734162\/torpedo-cf"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0102|cit102","first-page":"326, Abstract n","article-title":"A randomized pilot study of continuous versus intermittent infusion piperacillin-tazobactam for the treatment of pulmonary exacerbations in patients with cystic fibrosis [abstract]","volume":"48 Suppl 36","author":"Turner","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0103|cit103","unstructured":"Wesley AW Quested C Edgar BW Lennon DR A double-blind comparison of ceftazidime with tobramycin and ticarcillin in the treatment of exacerbations of pseudomonas chest infection in children with cystic fibrosis [abstract] Proceedings of the 10th International Cystic Fibrosis Congress; 1988 March 5-10; Sydney, Australia. (Excerpta Medica, Asia Pacific Congress Series, No. 74) 1988 13"},{"issue":"19","key":"10.1002\/14651858.CD002007.pub5-BIB0104|cit104","first-page":"262","article-title":"Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]","volume":"28","author":"Watson","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1183\/09031936.02.00221602","article-title":"Once-daily tobramycin in the treatment of adult patients with cystic fibrosis","volume":"19","author":"Whitehead","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"Suppl","key":"10.1002\/14651858.CD002007.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0300-2977(99)90103-1","article-title":"Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]","volume":"54","author":"Whitehead","year":"1999","journal-title":"The Netherlands Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0107|cit107","first-page":"939","article-title":"Cystic fibrosis lung inflammation: early, sustained and severe","volume":"151","author":"Cantin","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9028","key":"10.1002\/14651858.CD002007.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(96)05169-0","article-title":"Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic","volume":"348","author":"Cheng","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD002007.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD002007.pub5-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"European Journal of Human Genetics"},{"issue":"9","key":"10.1002\/14651858.CD002007.pub5-BIB0112|cit112","first-page":"802-808","article-title":"Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations","volume":"180","author":"P A\u00a0et al\u00a0and the Clinical Practice Guidelines for Pulmonary Therapies Committee","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002007.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD002007.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0115|cit115","unstructured":"Higgins JP Altman DG Sterne JA on behalf of the CSMG and the CBMG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.me.44.020193.000245","article-title":"Antibiotic therapy for chronic infection of pseudomonas in the lung","volume":"44","author":"Hoiby","year":"1993","journal-title":"Annual Review of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002007.pub5-BIB0117|cit117","first-page":"172","article-title":"Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: effects of tobramycin","volume":"9","author":"Katbamna","year":"1998","journal-title":"Journal of the American Academy of Audiology"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0118|cit118","volume-title":"The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs","author":"Kucers","year":"1997"},{"issue":"7159","key":"10.1002\/14651858.CD002007.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/bmj.317.7159.612","article-title":"Antimicrobial resistance: bacteria on the defence. Resistance stems from misguided efforts to try to sterilise our environment","volume":"317","author":"Levy","year":"1998","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD002007.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02961666","article-title":"Aminoglycoside induced ototoxicity in patients with cystic fibrosis","volume":"160","author":"Mulherin","year":"1991","journal-title":"Irish Journal of Medical Science"},{"issue":"6","key":"10.1002\/14651858.CD002007.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MCP.0b013e32833eebfd","article-title":"Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity","volume":"16","author":"Prayle","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/clinids\/23.3.532","article-title":"Antibiotic susceptibility of multiply resistant\u00a0Pseudomonas aeruginosa\u00a0isolated from patients with cystic fibrosis, including candidates for transplantation","volume":"23","author":"Saiman","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1002\/14651858.CD002007.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical Evidence of Bias","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1478-4505-4-25","article-title":"Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation","volume":"4","author":"Schunemann","year":"2006","journal-title":"Health Research Policy & Systems"},{"issue":"5","key":"10.1002\/14651858.CD002007.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1378\/chest.123.5.1495","article-title":"Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis","volume":"123","author":"Smith","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0126|cit126","unstructured":"Sterne JA Egger M Moher D on behalf of the Cochrane Bias Methods Group Chapter 10. Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD002007.pub5-BIB0127|cit127","unstructured":"UK Cystic Fibrosis Trust Antibiotic Working Group Antibiotic treatment for cystic fibrosis - 3rd edition www.cysticfibrosis.org.uk\/the-work-we-do\/resources-for-cf-professionals\/consensus-documents"},{"issue":"7360","key":"10.1002\/14651858.CD002007.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/bmj.325.7360.381","article-title":"Systematic reviews and lifelong diseases","volume":"325","author":"Elphick","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD002007.pub5-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002007.pub2","article-title":"Single versus combination intravenous antibiotic therapy for people with cystic fibrosis","author":"Elphick","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002007.pub5-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002007.pub3","article-title":"Single versus combination intravenous antibiotic therapy for people with cystic fibrosis","author":"Elphick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T03:49:38Z","timestamp":1654919378000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002007.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":130,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002007.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}